Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT06192966 Terminated - Clinical trials for Urinary Tract Infections

Effect of Probiotics on Recurrent Urinary Tract Infections

CYSCARE
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Randomized clinical trial to evaluate the effect of a probiotic mixture of Lactobacillus plantarum on recurrent urinary tract infections in women. Secondary outcomes comprise variation in vaginal/perianal microbiota, product tolerability, safety and consumer's satisfaction with the product.

NCT ID: NCT05942820 Terminated - Clinical trials for Bacterial Infections

The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers

Start date: August 30, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of BWC0977 when administered to healthy adult volunteers.

NCT ID: NCT05788185 Terminated - COVID-19 Clinical Trials

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

Start date: March 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.

NCT ID: NCT05674448 Terminated - Clinical trials for Chronic Hepatitis B and Hepatitis D Co-infection

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label phase IIa study of HH-003 to evaluate its antiviral activity and safety in subjects with chronic hepatitis B and hepatitis D co-infection. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.

NCT ID: NCT05603624 Terminated - Chorioamnionitis Clinical Trials

Effect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term

Start date: September 2, 2021
Phase: N/A
Study type: Interventional

This prospective randomized controlled study examines whether the type of glove used (sterile vs clean) for cervical examination to assess progression in labor impacts the rates of intrapartum and/or postpartum infection in patients during labor or induction of labor at term.

NCT ID: NCT05593770 Terminated - COVID-19 Clinical Trials

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

NECTAR
Start date: October 27, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

NCT ID: NCT05526807 Terminated - Clinical trials for Clostridioides Difficile Infection

Ursodeoxycholic Acid in C. Difficile Infection

Start date: May 8, 2019
Phase: N/A
Study type: Interventional

The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid

NCT ID: NCT05420077 Terminated - COVID-19 Clinical Trials

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

Start date: September 12, 2022
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single intramuscular injection in healthy adults. Three dose levels will be evaluated, with progression from low- to high-dose level based on the assessment of safety and tolerability. The study will be conducted at one or more sites in Australia.

NCT ID: NCT05379452 Terminated - SARS-CoV2 Infection Clinical Trials

Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai

Start date: March 1, 2022
Phase:
Study type: Observational

Since March 2022, there are an outbreak of SARS-CoV-2 infection (Omicron) in Shanghai. This cohort study aims to analysis the clinical outcomes of neonates born to mothers with SARS-CoV-2 infection.

NCT ID: NCT05305040 Terminated - Clinical trials for Cytomegalovirus Infections

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Prevent
Start date: March 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.